API Suppliers
US DMFs Filed
CEP/COS Certifications
JDMFs Filed
Other Certificates
Other Suppliers
USA (Orange Book)
Europe
Canada
Australia
0
South Africa
Uploaded Dossiers
U.S. Medicaid
Annual Reports
0
65
PharmaCompass offers a list of Dextromethorphan Hydrobromide API manufacturers, exporters & distributors, which can be sorted by GMP, USDMF, JDMF, KDMF, CEP (COS), WC, Price,and more, enabling you to easily find the right Dextromethorphan Hydrobromide manufacturer or Dextromethorphan Hydrobromide supplier for your needs.
Send us enquiries for free, and we will assist you in establishing a direct connection with your preferred Dextromethorphan Hydrobromide manufacturer or Dextromethorphan Hydrobromide supplier.
PharmaCompass also assists you with knowing the Dextromethorphan Hydrobromide API Price utilized in the formulation of products. Dextromethorphan Hydrobromide API Price is not always fixed or binding as the Dextromethorphan Hydrobromide Price is obtained through a variety of data sources. The Dextromethorphan Hydrobromide Price can also vary due to multiple factors, including market conditions, regulatory modifications, or negotiated pricing deals.
A Dextromethorphan polistirex manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Dextromethorphan polistirex, including repackagers and relabelers. The FDA regulates Dextromethorphan polistirex manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Dextromethorphan polistirex API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
click here to find a list of Dextromethorphan polistirex manufacturers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PhamaCompass.
A Dextromethorphan polistirex supplier is an individual or a company that provides Dextromethorphan polistirex active pharmaceutical ingredient (API) or Dextromethorphan polistirex finished formulations upon request. The Dextromethorphan polistirex suppliers may include Dextromethorphan polistirex API manufacturers, exporters, distributors and traders.
click here to find a list of Dextromethorphan polistirex suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.
A Dextromethorphan polistirex DMF (Drug Master File) is a document detailing the whole manufacturing process of Dextromethorphan polistirex active pharmaceutical ingredient (API) in detail. Different forms of Dextromethorphan polistirex DMFs exist exist since differing nations have different regulations, such as Dextromethorphan polistirex USDMF, ASMF (EDMF), JDMF, CDMF, etc.
A Dextromethorphan polistirex DMF submitted to regulatory agencies in the US is known as a USDMF. Dextromethorphan polistirex USDMF includes data on Dextromethorphan polistirex's chemical properties, information on the facilities and procedures used, and details about packaging and storage. The Dextromethorphan polistirex USDMF is kept confidential to protect the manufacturer’s intellectual property.
click here to find a list of Dextromethorphan polistirex suppliers with USDMF on PharmaCompass.
The Pharmaceuticals and Medical Devices Agency (PMDA) established the Japan Drug Master File (JDMF), also known as the Master File (MF), to permit Japanese and foreign manufacturers of drug substances, intermediates, excipients, raw materials, and packaging materials (‘Products’) to voluntarily register confidential information about the production and management of their products in Japan.
The Dextromethorphan polistirex Drug Master File in Japan (Dextromethorphan polistirex JDMF) empowers Dextromethorphan polistirex API manufacturers to present comprehensive information (e.g., production methods, data, etc.) to the review authority, i.e., PMDA (Pharmaceuticals & Medical Devices Agency).
PMDA reviews the Dextromethorphan polistirex JDMF during the approval evaluation for pharmaceutical products. At the time of Dextromethorphan polistirex JDMF registration, PMDA checks if the format is accurate, if the necessary items have been included (application), and if data has been attached.
click here to find a list of Dextromethorphan polistirex suppliers with JDMF on PharmaCompass.
In Korea, the Ministry of Food and Drug Safety (MFDS) is in charge of regulating pharmaceutical products and services.
Pharmaceutical companies submit a Dextromethorphan polistirex Drug Master File in Korea (Dextromethorphan polistirex KDMF) to the MFDS, which includes comprehensive information about the production, processing, facilities, materials, packaging, and testing of Dextromethorphan polistirex. The MFDS reviews the Dextromethorphan polistirex KDMF as part of the drug registration process and uses the information provided in the Dextromethorphan polistirex KDMF to evaluate the safety and efficacy of the drug.
After submitting a Dextromethorphan polistirex KDMF to the MFDS, the registered manufacturer can provide importers or distributors with the registration number without revealing confidential information to Korean business partners. Applicants seeking to register their Dextromethorphan polistirex API can apply through the Korea Drug Master File (KDMF).
click here to find a list of Dextromethorphan polistirex suppliers with KDMF on PharmaCompass.
A Dextromethorphan polistirex CEP of the European Pharmacopoeia monograph is often referred to as a Dextromethorphan polistirex Certificate of Suitability (COS). The purpose of a Dextromethorphan polistirex CEP is to show that the European Pharmacopoeia monograph adequately controls the purity of Dextromethorphan polistirex EP produced by a given manufacturer. Suppliers of raw materials can prove the suitability of Dextromethorphan polistirex to their clients by showing that a Dextromethorphan polistirex CEP has been issued for it. The manufacturer submits a Dextromethorphan polistirex CEP (COS) as part of the market authorization procedure, and it takes on the role of a Dextromethorphan polistirex CEP holder for the record. Additionally, the data presented in the Dextromethorphan polistirex CEP (COS) is managed confidentially and offers a centralized system acknowledged by numerous nations, exactly like the Dextromethorphan polistirex DMF.
A Dextromethorphan polistirex CEP (COS) is recognised by all 36 nations that make up the European Pharmacopoeia Convention. Dextromethorphan polistirex CEPs may be accepted in nations that are not members of the Ph. Eur. at the discretion of the authorities there.
click here to find a list of Dextromethorphan polistirex suppliers with CEP (COS) on PharmaCompass.
A Dextromethorphan polistirex written confirmation (Dextromethorphan polistirex WC) is an official document issued by a regulatory agency to a Dextromethorphan polistirex manufacturer, verifying that the manufacturing facility of a Dextromethorphan polistirex active pharmaceutical ingredient (API) adheres to the Good Manufacturing Practices (GMP) regulations of the importing country. When exporting Dextromethorphan polistirex APIs or Dextromethorphan polistirex finished pharmaceutical products to another nation, regulatory agencies frequently require a Dextromethorphan polistirex WC (written confirmation) as part of the regulatory process.
click here to find a list of Dextromethorphan polistirex suppliers with Written Confirmation (WC) on PharmaCompass.
National Drug Code is a comprehensive database maintained by the FDA that contains information on all drugs marketed in the US. This directory includes information about finished drug products, unfinished drug products, and compounded drug products, including those containing Dextromethorphan polistirex as an active pharmaceutical ingredient (API).
The FDA updates the NDC directory daily. The NDC numbers for Dextromethorphan polistirex API and other APIs are published in this directory by the FDA.
The NDC unfinished drugs database includes product listing information submitted for all unfinished drugs, such as active pharmaceutical ingredients (APIs), drugs intended for further processing and bulk drug substances for compounding.
Pharmaceutical companies that manufacture Dextromethorphan polistirex as an active pharmaceutical ingredient (API) must furnish the FDA with an updated record of all drugs that they produce, prepare, propagate, compound, or process for commercial distribution in the US at their facilities.
The NDC directory also contains data on finished compounded human drug products that contain Dextromethorphan polistirex and are produced by outsourcing facilities. While these outsourcing facilities are not mandated to assign a Dextromethorphan polistirex NDC to their finished compounded human drug products, they may choose to do so.
click here to find a list of Dextromethorphan polistirex suppliers with NDC on PharmaCompass.
Dextromethorphan polistirex Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Dextromethorphan polistirex GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Dextromethorphan polistirex GMP manufacturer or Dextromethorphan polistirex GMP API supplier for your needs.
A Dextromethorphan polistirex CoA (Certificate of Analysis) is a formal document that attests to Dextromethorphan polistirex's compliance with Dextromethorphan polistirex specifications and serves as a tool for batch-level quality control.
Dextromethorphan polistirex CoA mostly includes findings from lab analyses of a specific batch. For each Dextromethorphan polistirex CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Dextromethorphan polistirex may be tested according to a variety of international standards, such as European Pharmacopoeia (Dextromethorphan polistirex EP), Dextromethorphan polistirex JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Dextromethorphan polistirex USP).